{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-029524","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.800702+00:00","generated_at":"2026-05-16T06:27:51.849106+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted","bullets":["Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.","Key secondary endpoint CGI-S also missed (p=0.522).","eDSP well tolerated; most common adverse events pruritis and pyrexia.","Company to cease clinical development of eDSP and explore available options.","Phase 3 NEAT trial enrolled 105 patients with Ataxia-Telangiectasia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-029524","json":"https://secwatch.observer/filing/0001193125-26-029524.json","markdown":"https://secwatch.observer/filing/0001193125-26-029524.md","text":"https://secwatch.observer/filing/0001193125-26-029524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526029524/0001193125-26-029524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526029524/d61547d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:27:51.849106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}